Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sorafenib Tosylate

FDA-approved product (tablet, oral), marketed as Nexavar, Sorafenib Tosylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Sorafenib Tosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chromophobe renal cell carcinoma
  • Clear cell renal carcinoma
  • Hepatocellular carcinoma
  • Papillary renal cell carcinoma
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sorafenib Tosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sorafenib Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

    NCT00499525 · start 2007-06

    Registered record
    Registry ID
    NCT00499525
    Conditions
    Breast Cancer
    Interventions
    paclitaxel; sorafenib tosylate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2007-06
    Completion
    2022-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionpaclitaxel; sorafenib tosylate; placebo
    PhasePhase 2
    Registry statusUnknown

  • Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

    NCT00811759 · start 2007-06

    Registered record
    Registry ID
    NCT00811759
    Conditions
    Melanoma (Skin)
    Interventions
    sorafenib tosylate; temozolomide; gene expression analysis; mutation analysis; laboratory biomarker analysis; pharmacological study; biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2007-06
    Completion
    Not recorded
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin)
    Interventionsorafenib tosylate; temozolomide; gene expression analysis; mutation analysis +3 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

    NCT00538005 · start 2007-05

    Registered record
    Registry ID
    NCT00538005
    Conditions
    Melanoma (Skin)
    Interventions
    bevacizumab; oxaliplatin; sorafenib tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2007-05
    Completion
    Not recorded
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin)
    Interventionbevacizumab; oxaliplatin; sorafenib tosylate
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

    NCT00445588 · start 2007-01

    Registered record
    Registry ID
    NCT00445588
    Conditions
    Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventions
    erlotinib hydrochloride; sorafenib tosylate; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2009-08
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventionerlotinib hydrochloride; sorafenib tosylate; pharmacological study
    PhasePhase 2
    Registry statusCompleted

  • Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

    NCT00541021 · start 2006-12

    Registered record
    Registry ID
    NCT00541021
    Conditions
    Pancreatic Cancer
    Interventions
    gemcitabine hydrochloride; sorafenib tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-12
    Completion
    Not recorded
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    Interventiongemcitabine hydrochloride; sorafenib tosylate
    PhasePhase 3
    Registry statusUnknown

  • Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

    NCT00387751 · start 2006-08

    Registered record
    Registry ID
    NCT00387751
    Conditions
    Recurrent Melanoma; Stage III Skin Melanoma; Stage IV Skin Melanoma
    Interventions
    Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2010-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Melanoma; Stage III Skin Melanoma; Stage IV Skin Melanoma
    InterventionBevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Sorafenib Tosylate
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

    NCT00335764 · start 2006-04

    Registered record
    Registry ID
    NCT00335764
    Conditions
    Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventions
    sorafenib tosylate; erlotinib hydrochloride; tipifarnib; temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2012-09
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventionsorafenib tosylate; erlotinib hydrochloride; tipifarnib; temsirolimus
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    NCT00253578 · start 2006-03

    Registered record
    Registry ID
    NCT00253578
    Conditions
    Refractory Multiple Myeloma
    Interventions
    sorafenib tosylate; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Multiple Myeloma
    Interventionsorafenib tosylate; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

    NCT00112905 · start 2005-10

    Registered record
    Registry ID
    NCT00112905
    Conditions
    Adenocarcinoma of the Bladder; Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Squamous Cell Carcinoma of the Bladder; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
    Interventions
    sorafenib tosylate; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2005-10
    Completion
    2008-03
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Bladder; Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer +9 more
    Interventionsorafenib tosylate; laboratory biomarker analysis
    PhasePhase 2
    Registry statusTerminated

  • Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

    NCT00278382 · start 2005-10

    Registered record
    Registry ID
    NCT00278382
    Conditions
    Anaplastic Large Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma
    Interventions
    sorafenib tosylate; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-10
    Completion
    Not recorded
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma
    Interventionsorafenib tosylate; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

    NCT00265798 · start 2005-09-14

    Registered record
    Registry ID
    NCT00265798
    Conditions
    Gastrointestinal Stromal Tumor
    Interventions
    Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2005-09-14
    Completion
    2027-03-31
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor
    InterventionSorafenib Tosylate
    PhasePhase 2
    Registry statusActive not recruiting

  • Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

    NCT00245102 · start 2005-09

    Registered record
    Registry ID
    NCT00245102
    Conditions
    Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Leiomyosarcoma; Adult Malignant Fibrous Histiocytoma; Adult Neurofibrosarcoma; Adult Synovial Sarcoma; Ovarian Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Uterine Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Uterine Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IV Uterine Sarcoma; Uterine Carcinosarcoma; Uterine Leiomyosarcoma
    Interventions
    sorafenib tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2011-03
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Leiomyosarcoma; Adult Malignant Fibrous Histiocytoma +11 more
    Interventionsorafenib tosylate
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

    NCT00255658 · start 2005-09

    Registered record
    Registry ID
    NCT00255658
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    sorafenib tosylate; temsirolimus; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-09
    Completion
    2007-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionsorafenib tosylate; temsirolimus; laboratory biomarker analysis
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

    NCT00121251 · start 2005-06-03

    Registered record
    Registry ID
    NCT00121251
    Conditions
    Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    Interventions
    Capecitabine; Gemcitabine Hydrochloride; Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2005-06-03
    Completion
    2017-03-14
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    InterventionCapecitabine; Gemcitabine Hydrochloride; Sorafenib Tosylate
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

    NCT00131911 · start 2005-06

    Registered record
    Registry ID
    NCT00131911
    Conditions
    Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Neuroendocrine Tumor; Pancreatic Polypeptide Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma; WDHA Syndrome
    Interventions
    sorafenib tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-06
    Completion
    2013-04
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor +6 more
    Interventionsorafenib tosylate
    PhasePhase 2
    Registry statusCompleted